Longboard Pharmaceuticals
Works in Genetic & rare · Neurology · Oncology · Psychiatry
Longboard Pharmaceuticals is a clinical trial sponsor. It has 3 active clinical trials with 787 planned participants, in Genetic & rare, Neurology, Oncology and Psychiatry. Since 2021 it has completed 2 trials and stopped 0 early.
Trial track record · since 2021
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Longboard Pharmaceuticals
Longboard Pharmaceuticals is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 787 planned participants, in Genetic & rare, Neurology, Oncology, Psychiatry. Since 2021 it has completed 2 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Longboard Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-14.
Approve Suite is not affiliated with Longboard Pharmaceuticals.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.